Anshuman P. Malaviya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Anshuman P. Malaviya has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Aisla Bosworth
2 shared publicationsAndrew J. K. Östör
2 shared publicationsDavid Marshall
2 shared publicationsErnest Choy
2 shared publicationsGary Wright
2 shared publicationsJill Bloxham
2 shared publications
Latest Publications
- Open Access
- 8 August 2024
- Published by BMJ in BMJ Case Reports
- Vol. 17 (8) , e259439
FGF23-secreting sinonasal tumour presenting with acute subdural haemorrhage and tumour-induced osteomalacia
A female in her 50s developed a headache, collapsed and was noted to have an acute atraumatic subdural haemorrhage (SDH) requiring surgical evacuation and intracranial pressure-directed therapy. Her background included recurrent epistaxis, severe generalised bone pain and multiple insufficiency fractures and an undifferentiated autoimmune connective tissue disease. Chronic hypophosphataemia, elevated alkaline phosphatase and raised fibroblast growth factor 23 (FGF23) were also noted. An MRI head and subsequent 68Ga CT/positron emission tomography scan demonstrated an intensely avid tumour in the right ethmoid sinus, extending intracranially. Phosphate was aggressively replaced, and alfacalcidol was initiated to circumvent the effects of FGF23 on her kidneys and bone minerals. The tumour was biopsied and then definitively resected via combined endonasal and craniotomy approaches, resulting in good clinical improvement. FGF23 titre and serum phosphate both normalised leaving the diagnosis of a phosphaturic mesenchymal tumour-secreting FGF23, leading to tumour-induced osteomalacia.
- 8 August 2024
- Published by BMJ in BMJ Case Reports
- Vol. 17 (8) , e259439
Open AccessFGF23-secreting sinonasal tumour presenting with acute subdural haemorrhage and tumour-induced osteomalacia
A female in her 50s developed a headache, collapsed and was noted to have an acute atraumatic subdural haemorrhage (SDH) requiring surgical evacuation and intracranial pressure-directed therapy. Her background included recurrent epistaxis, severe generalised bone pain and multiple insufficiency fractures and an undifferentiated autoimmune connective tissue disease. Chronic hypophosphataemia, elevated alkaline phosphatase and raised fibroblast growth factor 23 (FGF23) were also noted. An MRI head and subsequent 68Ga CT/positron emission tomography scan demonstrated an intensely avid tumour in the right ethmoid sinus, extending intracranially. Phosphate was aggressively replaced, and alfacalcidol was initiated to circumvent the effects of FGF23 on her kidneys and bone minerals. The tumour was biopsied and then definitively resected via combined endonasal and craniotomy approaches, resulting in good clinical improvement. FGF23 titre and serum phosphate both normalised leaving the diagnosis of a phosphaturic mesenchymal tumour-secreting FGF23, leading to tumour-induced osteomalacia.
- Open Access
- 13 September 2014
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 53 (10) , 1914
The 2013 BSR and BHPR guideline for the use of intravenous tocilizumab in the treatment of adult patients with rheumatoid arthritis
Rheumatology 2014;53: 1344–1346 , doi: 10.1093/rheumatology/keu168
- 13 September 2014
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 53 (10) , 1914
Open AccessThe 2013 BSR and BHPR guideline for the use of intravenous tocilizumab in the treatment of adult patients with rheumatoid arthritis
Rheumatology 2014;53: 1344–1346 , doi: 10.1093/rheumatology/keu168
- Open Access
- 10 May 2014
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 53 (7) , 1344-1346
The 2013 BSR and BHPR guideline for the use of intravenous tocilizumab in the treatment of adult patients with rheumatoid arthritis
RA is a chronic systemic inflammatory disorder with a prevalence of up to 1%. In the absence of adequate treatment, progressive joint deformity and loss of function occurs with associated premature cardiovascular morbidity. Tocilizumab (TCZ) [1], a humanized anti IL-6 receptor (anti IL-6R) antibody, has been shown in several large randomized controlled trials to be efficacious and well tolerated in the treatment of RA.
- 10 May 2014
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 53 (7) , 1344-1346
Open AccessThe 2013 BSR and BHPR guideline for the use of intravenous tocilizumab in the treatment of adult patients with rheumatoid arthritis
RA is a chronic systemic inflammatory disorder with a prevalence of up to 1%. In the absence of adequate treatment, progressive joint deformity and loss of function occurs with associated premature cardiovascular morbidity. Tocilizumab (TCZ) [1], a humanized anti IL-6 receptor (anti IL-6R) antibody, has been shown in several large randomized controlled trials to be efficacious and well tolerated in the treatment of RA.
- 26 June 2012
- Published by Wiley in Arthritis & Rheumatism
- Vol. 64 (7) , 2403
Clinical image: The Harlequin sign-benign blush or the bearer of bad news?
- 26 June 2012
- Published by Wiley in Arthritis & Rheumatism
- Vol. 64 (7) , 2403
Clinical image: The Harlequin sign-benign blush or the bearer of bad news?